We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gentronix and BioQuanta to Distribute Mitoxis-Functional Metabolic Platform.

By LabMedica International staff writers
Posted on 20 Dec 2011
Gentronix Ltd. More...
(Manchester, United Kingdom), the specialist genotoxicity assay provider and BioQuanta SA (Paris, France), a French company engaged in the implementation of predictive and personalized medicine, have signed an agreement covering the commercialization of the Mitoxis functional metabolomics platform from BioQuant. Mitoxis is a novel assay platform for evaluating the metabolic impact of any molecule, as well as detecting mitochondrial toxicity.

Gentronix will become a worldwide distributor of Mitoxis services giving customers access to over 70 discrete assays central to a deeper understanding of cell health. This comprehensive range of assays covers key functional metabolisms important for the early detection of toxicity liabilities, including the electron-transport chain, oxidative stress, cellular energy status, inflammation, and cell death.

Mitoxis was developed on highly automated analyzers used in clinical biology, and delivers results with the precision of clinical diagnostics. The Mitoxis approach allows the simultaneous analysis of more than 30 parameters on the same reduced sample volume of < 5µL, with limited or no sample preparation. With an overall coefficient of variation (CV) < 4%, intersample variability is lowered, leading to increased confidence in the results and a better understanding of interdependencies between parameters. Mitoxis provides unmatched results to evaluate side effects of exogenous molecules (therapeutic, cosmetic, or industrial) on the main transversal metabolic pathways of the cell.

The platform was developed to meet the same performance criteria of standard operating procedures in place for clinical biology, and it is the result of expertise gained from performing millions of tests per year routinely in a French public hospital.

Dr. Steve Beasley, Commercial Director at Gentronix said, "This agreement allows Gentronix to further expand its range of services across all of the sectors we currently serve to provide our customers access to a wide range of cell health assays of unparalleled accuracy. We have an expanding customer base that will benefit from access to these highly accurate metabolomics assays."

BioQuanta is a biotechnology company engaged in the implementation of predictive and personalized medicine. The company aims to become a major player in the biopharmaceutical R&D by contributing to the development of innovative drugs, and powerful diagnostic solutions to categorize patients.

Gentronix provides services and solutions that ensure safer products across a wide range of chemistry driven industries. The company's primary focus is on providing better hazard identification assays for genotoxicity through the use of its patented human cell GADD45a reporter assays GreenScreen HC and BlueScreen HC. Gentronix provides contract services for genotoxicity in these and related assays including Ames, Comet and Micronucleus tests, as well as a wide range of ADME and predictive toxicity endpoints.

Related Links:
Gentronix Ltd.
BioQuanta SA



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.